Celularity's Strategic Partner Announces Groundbreaking For Stem Cell & Regenerative Medicine Center In Asia Pacific
Celularity's Strategic Partner Announces Groundbreaking For Stem Cell & Regenerative Medicine Center In Asia Pacific
- Celularity is collaborating with its strategic partner, Genting Berhad, to bring Celularity placenta-derived allogeneic stem cell therapeutics to the Asia Pacific region
-
Genting Berhad announced groundbreaking on a new, state-of-the-art wellness and health center in Bali, Indonesia, that will utilize Celularity products
-
Strategic partnership positions Celularity to be a key supplier of innovative stem cell and regenerative medicine products for use in the Asia Pacific region
- Celularity正在与其战略伙伴云顶集团合作，将Celularity胎盘来源的同种异体干细胞治疗方案引入亚太地区
- 云顶集团宣布在印尼巴厘岛破土动工建设一座新的最先进的健康与保健中心，该中心将利用Celularity的产品
- 战略合作使Celularity有望成为亚太地区创新干细胞和再生医学产品的主要供应商
FLORHAM PARK, N.J., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a regenerative and cellular medicine company, today announced that its strategic partner, Genting Berhad, has broken ground on Fontaine Vitale, a state-of-the-art stem cell and regenerative medicine facility in the Sanur Special Economic Zone located in Bali, Indonesia. Fontaine Vitale will offer world-class cell therapies focused on wellness, aesthetics, and regenerative medicine to both local and international patients using placenta-derived stem cells manufactured by Celularity in its US facility, according to Genting Berhad's press release. The new center is expected to commence commercial operations towards the end of 2026.
新泽西州佛罗拉姆公园，2024年11月20日（全球新闻网）-- Celularity Inc.(纳斯达克:CELU)（"Celularity"），一家再生和细胞医学公司，今日宣布其战略伙伴云顶集团已在印尼巴厘岛的圣诺特别经济区破土动工建设Fontaine Vitale，这是一座最先进的干细胞和再生医学设施。Fontaine Vitale将提供世界级的细胞治疗，专注于健康、美学和再生医学，面向当地和国际患者，使用由Celularity在其美国设施生产的胎盘来源干细胞，按照云顶集团的新闻稿，该中心预计将在2026年底开始商业运营。
